Skip to main content

Table 1 Characteristics of individuals living with HIV at diagnosis and follow up (total N = 1160)

From: Determinants of AIDS and non-AIDS related mortality among people living with HIV in Shiraz, southern Iran: a 20-year retrospective follow-up study

Baseline Characteristics

Entire cohort

AIDS-related mortality

Non-AIDS-related mortality

All-cause mortality

Overall

1160 (100)*

251 (21.6)

140 (12.1)

391 (33.7)

Gender

 Men

857 (73.9)

215 (25.1)

136 (15.9)

351 (41.0)

 Women

303 (26.1)

36 (11.9)

4 (1.3)

40 (13.2)

Age

 Median (Q1, Q3)

34 (29–40)

36 (30–43)

35 (30–41)

35 (30–42)

 < 30

309 (26.6)

55 (17.8)

34 (11.0)

89 (28.8)

 30–39

545 (47.0)

108 (19.8)

61 (11.2)

169 (31.0)

 > =40

306 (26.4)

88 (28.8)

45 (14.7)

133 (43.5)

Marital status

 Married

526 (45.3)

101 (19.2)

48 (9.1)

149 (28.3)

 Single

303 (26.2)

81(26.7)

50 (16.5)

131 (43.2)

 Widowed/divorced

331 (28.5)

69 (20.8)

42 (12.7)

111 (3.4)

Education

 Less than secondary

403 (34.7)

93 (23.0)

50 (12.4)

143 (35.5)

 Secondary or more

757 (65.3)

158 (20.8)

90 (11.8)

237 (31.3)

Employment

 Employed

549 (47.3)

112 (20.4)

77 (14.0)

189 (34.4)

 Unemployed

611 (52.7)

139 (22.7)

63 (10.3)

202 (33.1)

Incarceration history

 No

392 (33.8)

48 (12.2)

10 (2.6)

58 (14.8)

 Yes

768 (66.2)

203 (26.4)

130 (16.9)

333 (43.4)

Mode of HIV transmission

 Sexual

344 (29.7)

46 (13.4)

9 (2.6)

55 (16.0)

 Injection drug use

733 (63.2)

185(25.2)

123 (16.8)

308 (42.0)

 Othersa

83 (7.1)

20 (24.1)

8 (9.6)

28(33.7)

 CD4 count

Median (Q1, Q3)

215 (102,352)

238 (127,254)

133 (63,260)

163 (78,300)

Year HIV was diagnosed

 Before 2011

712 (61.4)

46 (6.4)

35 (4.9)

81 (11.3)

 2011–2014

306 (26.4)

145 (47.3)

69 (22.5)

214 (69.8)

 2015–2017

142 (12.2)

60 (42.2)

36 (25.3)

96(67.5)

Covariates measured at follow-up

 Drug use status

  No drug use

307 (26.5)

36 (11.7)

5 (1.6)

41 (16.0)

  On methadone therapy

568 (49.0)

101 (17.8)

65 (11.4)

166 (42.0)

  Drug users

258 (24.5)

114 (44.2)

70 (27.1)

184 (33.7)

Linkage to HIV care

 No

219 (18.9)

124 (56.6)

72 (32.9)

196 (89.5)

 Yes

941(81.1)

127 (13.5)

68 (7.2)

195 (20.7)

Responded HAART 6 month after initiationb

 No

392 (33.8)

239 (61)

97 (24.7)

232 (59.2)

 Yes

768 (66.2)

12 (1.6)

43 (5.6)

159 (20.7)

Late HIV diagnosis

 No

629 (54.2)

136 (21.6)

96 (15.3)

232 (36.9)

 Yes

531 (45.8)

115 (21.7)

44 (8.3)

159 (29.9)

TB status

 Negative

1048 (90.3)

205 (19.6)

123 (11.7)

328 (31.3)

 Positive

112 (9.7)

46 (41.0)

17 (15.2)

63 (56.3)

PCP prophylaxis

 No

480 (41.4)

108 (22.5)

77 (16.0)

185 (38.5)

 Yes

680 (58.6)

143 (21)

63 (9.3)

206 (30.3)

HCV positive co-infection

 Negative

500 (43.1)

116 (23.2)

33 (6.6)

149 (29.8)

 Positive

660 (56.9)

135 (20.5)

107 (16.2)

242 (36.7)

HBV positive co-infection

 Negative

1078 (92.9)

231 (21.4)

127 (11.8)

358 (33.2)

 Positive

82 (7.1)

20 (24.4)

13 (15.9)

33 (40.2)

Last clinical stage

 1,2

832 (71.7)

24 (2.9)

91 (10.9)

115 (13.8)

 3,4

328 (28.3)

227 (69.2)

49 (14.9)

276 (84.1)

  1. * Data are presented as N (%)
  2. aOther modes of transmission included: who infected HIV with unknown cause, blood transition or through dentistry
  3. binclude those showing an improvement in clinical factors or increased CD4 counts 6 months after HAART treatment based on medical records and physicians’ comments